Floatz logo

Romidepsin

Wiskott-Aldrich Syndrome

Masonic Cancer Center, University of MinnesotaSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Wiskott-Aldrich Syndrome cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Roswell Park Cancer Institute
Phase 2BB
Evomela
Washington University School of Medicine
Phase 2BB
TACROLIMUS
Roswell Park Cancer Institute
Phase 2BB
Fludarabine
Roswell Park Cancer Institute
Phase 2BB
Thiotepa
University of Florida
Phase 2BB

View all 19 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →